Glaxosmithkline Pharmaceuticals Ltd's Q4FY25 Quarter Results
- 14 May 2025
Result Summary
- Glaxosmithkline Pharmaceuticals Ltd reported a 2.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 17.7%.
- Its expenses for the quarter were up by 2.2% QoQ and 8.8% YoY.
- The net profit decreased 15.4% QoQ and increased 45.8% YoY.
- The earnings per share (EPS) of Glaxosmithkline Pharmaceuticals Ltd stood at 11.5 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 959.63 | 984.49 | 815.11 | -2.5% | 17.7% |
Total Expenses | 691.41 | 676.39 | 635.54 | 2.2% | 8.8% |
Profit Before Tax | 270.62 | 308.10 | 189.97 | -12.2% | 42.5% |
Tax | 76.14 | 78.22 | 56.54 | -2.7% | 34.7% |
Profit After Tax | 194.48 | 229.88 | 133.43 | -15.4% | 45.8% |
Earnings Per Share | 11.50 | 13.60 | 7.40 | -15.4% | 55.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Glaxosmithkline Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, engaged in the production and marketing of a wide range of pharmaceutical products. The company is known for its focus on producing innovative medicines and vaccines, contributing significantly to healthcare solutions globally. Recent developments within the company have not been specified in the given data. However, as part of a global pharmaceutical giant, the company typically invests in research and development to maintain a robust pipeline of products.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), Glaxosmithkline Pharmaceuticals Ltd reported a total income of ₹959.63 crores, which represents a decrease of 2.5% from the previous quarter (Q3FY25) where the income stood at ₹984.49 crores. However, when compared to the same quarter in the previous fiscal year (Q4FY24), where the total income was ₹815.11 crores, there was a significant year-over-year increase of 17.7%. This indicates a growth in revenue generation over the year, despite a slight dip from the preceding quarter.
Profitability
The company's profitability metrics reflect some fluctuations. For Q4FY25, the Profit Before Tax (PBT) was ₹270.62 crores, showing a quarter-over-quarter decline of 12.2% from ₹308.10 crores in Q3FY25. However, compared to the same period last year (Q4FY24), the PBT increased by 42.5% from ₹189.97 crores. The Profit After Tax (PAT) for Q4FY25 was ₹194.48 crores, down 15.4% from ₹229.88 crores in the previous quarter, yet up 45.8% from ₹133.43 crores year-over-year. Earnings Per Share (EPS) mirrored this trend, decreasing by 15.4% from the previous quarter to ₹11.50 but increasing by 55.4% from the previous year. These figures suggest improved profitability over the year but a decline in the immediate quarter.
Operating Metrics
Total expenses for Q4FY25 were ₹691.41 crores, reflecting an increase of 2.2% from the previous quarter’s ₹676.39 crores and an 8.8% rise from ₹635.54 crores in Q4FY24. The tax expense for the quarter was ₹76.14 crores, a slight decrease of 2.7% from Q3FY25’s ₹78.22 crores, but a 34.7% increase compared to ₹56.54 crores in the same quarter of the previous year. These metrics indicate an upward pressure on expenses and tax liabilities over the year, with a slight reduction in taxes quarter-over-quarter.
